Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

被引：702

作者：

Zhou, Bin-Bing S. ^{[1
]}

Zhang, Haiying ^{[2
]}

Damelin, Marc ^{[1
]}

Geles, Kenneth G. ^{[1
]}

Grindley, Justin C. ^{[1
]}

Dirks, Peter B. ^{[3
]}

机构：

[1] Wyeth Res, Oncol Discovery, Pearl River, NY 10965 USA

[2] Abbott Labs, Abbott Pk, IL 60064 USA

[3] Hosp Sick Children, Toronto, ON M4G 1X8, Canada

来源：

NATURE REVIEWS DRUG DISCOVERY | 2009年 / 8卷 / 10期

关键词：

CANCER STEM-CELLS; ACUTE MYELOID-LEUKEMIA; EPITHELIAL-MESENCHYMAL TRANSITION; ACUTE MYELOGENOUS LEUKEMIA; SIDE-POPULATION PHENOTYPE; SMALL-MOLECULE INHIBITOR; HUMAN BREAST-CANCER; ABILITY IN-VITRO; HEMATOPOIETIC STEM; SELF-RENEWAL;

D O I：

10.1038/nrd2137

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The hypothesis that cancer is driven by tumour-initiating cells (popularly known as cancer stem cells) has recently attracted a great deal of attention, owing to the promise of a novel cellular target for the treatment of haematopoietic and solid malignancies. Furthermore, it seems that tumour-initiating cells might be resistant to many conventional cancer therapies, which might explain the limitations of these agents in curing human malignancies. Although much work is still needed to identify and characterize tumour-initiating cells, efforts are now being directed towards identifying therapeutic strategies that could target these cells. This Review considers recent advances in the cancer stem cell field, focusing on the challenges and opportunities for anticancer drug discovery.

引用

页码：806 / 823

页数：18

共 206 条

[1]

Abraham BK, 2005, CLIN CANCER RES, V11, P1154

[2] Monoclonal antibody therapy of cancer [J].

Adams, GP ;

Weiner, LM .

NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157

[3] Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors [J].

Akala, Omobolaji O. ;

Park, In-Kyung ;

Qian, Dalong ;

Pihalja, Michael ;

Becker, Michael W. ;

Clarke, Michael F. .

NATURE, 2008, 453 (7192) :228-U12

[4] Therapeutic implications of cancer stem cells [J].

Al-Hajj, M ;

Becker, MW ;

Wichal, M ;

Weissman, I ;

Clarke, MF .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2004, 14 (01) :43-47

[5] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[6] Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model [J].

Anderson, SA ;

Glod, J ;

Arbab, AS ;

Noel, M ;

Ashari, P ;

Fine, HA ;

Frank, JA .

BLOOD, 2005, 105 (01) :420-425

[7]

Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940

[8] Pathways to Tumorigenesis-Modeling Mutation Acquisition in Stem Cells and Their Progeny [J].

Ashkenazi, Rina ;

Gentry, Sara N. ;

Jackson, Trachette L. .

NEOPLASIA, 2008, 10 (11) :1170-U22

[9] Inhibition of Smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis [J].

Athar, M ;

Li, CX ;

Tang, XW ;

Chi, SM ;

Zhang, XL ;

Kim, AL ;

Tyring, SK ;

Kopelovich, L ;

Hebert, J ;

Epstein, EH ;

Bickers, DR ;

Xie, JW .

CANCER RESEARCH, 2004, 64 (20) :7545-7552

[10] Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism [J].

Ayyanan, A ;

Civenni, G ;

Ciarloni, L ;

Morel, C ;

Mueller, N ;

Lefort, K ;

Mandinova, A ;

Raffoul, W ;

Fiche, M ;

Dotto, GP ;

Brisken, C .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (10) :3799-3804

← 1 2 3 4 5 6 7 8 9 10 →